The molecular basis of these disorders in patients lacking the V617F mutation was unclear.
在缺乏V617 F变异的那些病人中，这些病症的分子基础并不明显。
There is high frequency of JAK2 V617F mutation in myeloproliferative disorders and it could be used as the diagnostic marker for myeloproliferative disorders.
JAK2基因V617F突变在骨髓增殖性疾病中有较高的检出率，可作为骨髓增殖性疾病特异性诊断指标。
应用推荐